Development and preliminary experience with an ease of extractability rating system for prescription opioids

被引：19

作者：

Katz, N. P.

Buse, D. C.

Budman, S. H.

Venuti, S. Wing

Fernandez, K. C.

Benoit, C.

Bianchi, R.

Cooper, D.

Jasinski, D. R.

Smith, D. E.

Butler, S. F.

机构：

[1] Inflexxion Inc, Newton, MA 02464 USA

[2] Tufts Univ, Sch Med, Boston, MA 02111 USA

[3] Harvard Univ, Sch Med, Boston, MA USA

[4] Prescript Drug Res Ctr, Fairfax, VA USA

[5] Signature Consulting, Rockville, MD USA

[6] Johns Hopkins Bayview Med Ctr, Baltimore, MD USA

[7] Haight Ashbury Free Clin, San Francisco, CA USA

来源：

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY | 2006年 / 32卷 / 06期

关键词：

extractability; substance abuse; opioid; narcotic; Controlled Substances Act;

D O I：

10.1080/03639040500529093

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

One important factor in the abuse potential of an opioid product is the ease with which active drug can be extracted. There are currently no standards for testing or reporting extractability. This article describes the development of an Extractability Rating System for use by the pharmaceutical industry and regulators. Despite several limitations, this effort serves as a call for standardized testing and reporting so that products can be accurately rated, and should help establish goals for drug developers who wish to develop "abuse-resistant" opioid products.

引用

页码：727 / 746

页数：20

共 13 条

[1]

*AM PAIN SOC, 2004, PRINC AN US TREATM A

[2]

Bigne J.E., 2002, Qualitative Market Research: An International Journal, V5, P87, DOI [10.1108/13522750210423724, DOI 10.1108/13522750210423724]

[3] The bath water or the baby? [J].